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We were interested in the characteristics of Forsyth’s primer
pair and checked it by using the software ‘Primer 3’ as found
on the internet (http://www.genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi). ‘Primer 3’ picks polymerase chain reaction
(PCR) primers amplifying a particular region of a target gene
defined from a nucleotide sequence database, generates scores for
complementarities of the primer pairs and calculates melting
temperatures and GC-contents of primers and products. Important
for that is the complete entry of mRNA sequence of the target gene
from a molecular biology database (Burks, 1999).
In the case of the MMP-2 primers from Forsyth et al, ‘Primer 3’
could not identify the binding sites of both primers in the source
MMP-2 mRNA sequence (Accession number [AC]: JO3210;
identification code [ID]: HUMCN4GEL). Putative binding sites of
both MMP-2 primers were therefore checked by a Blast-Internet
program (http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/nph-new-
blast) comparing a nucleotide query sequence against a nucleotide
sequence database. The applied software falls back on four data-
bases (non-redundant sequences from GenBank, EMBL, DDBJ and
PDJ). To our surprise, the used MMP-2 primer sequences of
Forsyth et al produced significant alignments with regions of the
human tissue inhibitor TIMP-1 gene, exon 1 (AC: L47357; ID:
HUMTIMP1G), the human collagenease inhibitor mRNA (AC:
M59906; ID: HUMOGCA) and the human fibroblast collagenase
inhibitor mRNA (AC: M12670; ID: HUMFCI) but not with the
MMP-2 gene. However, the alignments with both collagenase
inhibitors were found only in 22 of the 25 input bases of the primers
and the Blast-program automatically cut off the first three bases.
After comparing the source mRNA sequence for both collage-
nase inhibitors mentioned above and the completed sequences of
the primers, we found one false base at the third position of the
5¢- (A instead of G) and at the 3¢-primer (C instead of A) both at
the 5¢-end. We also observed a print error in the reading direction
of the gelatinase A reverse primer (5¢ instead of 3¢). Consequently,
the size of the amplification product would be 686 bp instead of
the published product size of 473 bp.
In consequence of our investigation, we are uncertain whether the
authors really detected MMP-2 and not TIMP-1. The agarose gel
bands shown in Figure 1 cannot be considered as proof for the detec-
tion of the target gene and for the correct PCR product size since no
DNA molecular weight markers are present in the same gel run.
In addition to these data, we found that the product size for
MT1-MMP as cited in the same paper is not 548 bp but 530 bp and
that the used 5¢-primer for this gene contains a false cited base in
the third position from the 3¢-end (G instead of C).
Apart from drawing the interested reader’s attention to these
possible mistakes, the paper gives rise to the following general
recommendations:
• The selection of primers has to be documented in an easily
understandable manner to avoid serious mistakes
• Therefore, primer sequences should be specified by declara-
tion of the source of the target gene sequence (e.g. the
nucleotide sequence database used) and of the primer position
within the target sequence
• In addition, citation of the accession number (AC) and the
identification code (ID) of the investigated gene sequence
would give a definite relation between a nucleotid sequence
and its target gene.
Printing errors of nucleotide sequences of primers could thus
more easily be checked, and the suggested procedure gives a better
guarantee for correct citations and successful application of
published methods in molecular biology.
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Sir,
I am replying to the above letter, which was sent concerning
our paper ‘Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and
membrane type-matrix metalloproteinase-1 (MT1-MMP) are
involved in different aspects of the pathophysiology of malignant
gliomas’, Forsyth PA et al (1999) Br J Cancer 79: 1828–1835.
Jung et al point out that the primer sequences listed in our paper
for reverse transcription polymerase chain reaction (RT-PCR)
amplification of human gelatinase-A (MMP-2) are incorrect. The
sequences given in fact correspond to primer sequences used for
human TIMP-1 amplification, with additional BamHI and HinDIII
cloning sites at the 5¢-end of the oligonucleotides to allowLetters to the Editor 1613
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sub-cloning. This arose due to a mistake in transcribing informa-
tion from a larger table of MMP/TIMP oligonucleotide primer
sequences when the British Journal of Cancer paper was being put
together. However, this does not compromise the data reported in
the paper, which were obtained using the correct MMP-2
primer sequences forward = 5¢-GGCCCTGTCACTCCTGAGAT,
reverse = 5¢-GGCATCCAGGTTATCGGGGA, which as described
amplify a 474 bp PCR product. The methods that we have used for
MMP and TIMP quantification by RT-PCR are described in detail
in Wong et al (in press).
We are grateful to Jung et al for pointing out this error, and the
correct size of the MT1-MMP PCR product as 530 bp. There is
certainly a need for vigilance in the use of PCR as a research tool,
which we maintain in our own laboratories by subcloning and
sequence analysis of RT-PCR products to confirm their identities.
We agree that it is useful to identify the target gene sequences
used and the positions of primer pair combinations within those
sequences as a method of facilitating studies by other labs.
Consequently we have drawn up this information for the MMP-2,
MMP-9 and MT1-MMP targets used in our paper (Table 1).
However, we caution that even with such information in hand, it is
still necessary for other laboratories to confirm independently the
identities of the PCR products that they obtain, using appropriate
molecular criteria.
DR Edwards
School of Biological Sciences, University of East Anglia,
Norwich, Norfolk NR4 7TJ, UK
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Table 1 RT-PCR primer description
Target gene Primer sequence Target Position Product PCR
accession size cycle
number (bp) no.
Gelatinase-A GGCCCTGTCACTCCTGAGAT J03210 1337–1356 474 29
(MMP-2) GGCATCCAGGTTATCGGGGA 1810–1791
Gelatinase-B TGGACGATGCCTGCAACGTG NM 004994.1 1554–1573 455 33
(MMP-9) GTCGTGCGTGTCCAAAGGCA 2008–1989
MT1-MMP GCCCATTGGCCAGTTCTGGCGGG NM 004995.1 1178–1200 530 30
(MMP-14) CCTCGTCCACCTCAATGATGATC 1707–1685
GAPDH CGGAGTCAACGGATTTGGTCGTAT M33197 78–101 307 23
AGCCTTCTCCATGGTGGTGAAGAC 384–361
Sir,
We have read with great interest the article of Guerry and co-
workers ‘Prognostic value of histological and biological markers
in pharyngeal squamous cell carcinoma: a case-control study’
(Guerry et al, 1998). The authors present a comparison between
some histological features (grading, keratinization and vascular
emboli) and immunohistochemical features (expression of p53, c-
erb-B2, Rb and bcl-2) of primary tumour biopsies in two groups of
patients affected by pharyngeal cancer: patients who developed
distant metastasis (DM) and patients who did not. In the case-
control design each patient who developed a DM was matched to a
control patient with the same tumour site, the same nodal size and
level in the neck, and with an equal follow-up but free of DM. Out
of 65 patients there were 45 with positive neck nodes. It was found
that the risk for DM was halved in patients with tumours
expressing c-erb-B2 compared with patients with tumours
negative for c-erb-B2.
This result is of particular interest because it gives new perspec-
tive in the treatment planning and prognosis for these patients.
However, the design of this case-control study is not completely
correct.
Indeed, the two groups of patients with and without DM are
only clinically homogeneous. No data regarding the immunohisto-
chemical homogeneity of the neck nodes was presented. This is
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Prognostic value of histological and biological markers
in pharyngeal squamous cell carcinoma: a case-control
study